Meropenem Venus

Meropenem, the active ingredient in Meropenem Venus, is a carbapenem antibiotic presented as a strength/form for intravenous use. It treats severe infections caused by susceptible Gram‑negative and Gram‑positive bacteria in hospitalized patients.

GNH USA supplies Meropenem Venus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Meropenem is a broad‑spectrum carbapenem used to treat serious bacterial infections in the hospital setting.

- Complicated intra‑abdominal infection: eradicates the causative pathogens, aiding rapid resolution of infection. - Complicated urinary tract infection: provides effective bacterial clearance, reducing symptoms and preventing recurrence. - Nosocomial pneumonia: targets resistant organisms, improving pulmonary outcomes. - Bacterial meningitis: penetrates the cerebrospinal fluid to eliminate the infecting organisms. - Severe Gram‑negative and Gram‑positive infections: offers broad coverage for life‑threatening sepsis.

Adverse reactions may occur with any antibiotic therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Rash: erythematous skin eruption. - Injection site reaction: pain, erythema, or swelling at the infusion site. - Elevated liver enzymes: transient increase in hepatic transaminases. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Clostridioides difficile colitis: severe diarrhea due to overgrowth of C. difficile. - Anaphylaxis: acute, potentially life‑threatening hypersensitivity reaction. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: severe skin detachment. - Renal toxicity: acute kidney injury in susceptible individuals. - Neutropenia: marked reduction in neutrophil count.

Use meropenem with careful clinical assessment and monitoring.

- Renal function: adjust dosing in patients with impaired renal clearance. - Allergy: avoid in individuals with known hypersensitivity to carbapenems or beta‑lactams. - Pregnancy: prescribe only when the potential benefit justifies the potential risk to the fetus. - Valproic acid co‑administration: monitor for decreased valproate levels and possible seizure breakthrough. - Concomitant nephrotoxic drugs: monitor renal parameters closely. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Meropenem may interact with several medications, requiring clinical vigilance.

Major Interactions (Avoid): - Valproic acid: carbapenems reduce plasma valproate concentrations, increasing seizure risk. - CNS depressants: additive risk of seizures, especially in patients with pre‑existing CNS disorders. - Nephrotoxic agents: concurrent use may exacerbate renal impairment.

Moderate Interactions (Monitor Closely): - Loop diuretics: monitor electrolytes and renal function. - Aminoglycosides: assess for additive nephrotoxicity. - Warfarin: observe INR for potential anticoagulation changes.